Latest news
Debiopharm International SA Announces Phase III Positive Results for Triptorelin 6-month Formulation in the Management of Central Precocious Puberty (CPP)
Debiopharm International SA initiates clinical phase II study evaluating Debio 1450 in Staphylococcal skin infections
Debiopharm International SA announces results of 2 key oncology programs at 2015 AACR Conference
Debiopharm Diagnostics leads investment round in GenePOC with Emerillon Capital
FDA Grants Fast Track designation to Debiopharm Group’s antibiotic Debio 1450
Debiopharm Investment, Ardian, Nixdorf Foundation and Bernis today acquire Eco Delta solar activities
Debiopharm Investment becomes a minority shareholder in Haut-Lac International Bilingual School in St-Légier (VD)
Debiopharm Group™ presents advances of two key oncology clinical programs at the 26th EORTC-NCI-AACR symposium in Barcelona
Stay informed
Don't miss any latest news and announcements on Debiopharm Investment, subscribe to our newsletter.